Business
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT enables development of AFib-RVR under sNDA pathwayMilestone well-capitalized to launch and commercialize CARDAMYST with existing capital and royalty financingConference call and webcast December 15, 8:00 a.m. ET MONTREAL and CHARLOTTE, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc
About this update from Milestone Pharmaceuticals Inc.
[{"type":"image","alt":"Milestone Pharmaceuticals Inc.","displaySize":"","headline":null,"caption":"Milestone Pharmaceuticals Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":57,"url":"https://media.zenfs.com/en/globenewswire.com/a3e01b195c1ef10ed327d66d987e808c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YgaHOGiuZH1uIXCqN0ZsAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/a3e01b195c1ef10ed327d66d987e808c","width":300,"height":57}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT ","length":85,"tagName":"p"}]},{"val":[{"type":"text","content":"Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm","length":87,"tagName":"p"}]},{"val":[{"type":"text","content":"FDA approval in PSVT enables development of AFib-RVR under sNDA pathway","length":71,"tagName":"p"}]},{"val":[{"type":"text","content":"Milestone well-capitalized to launch and commercialize CARDAMYST with existing capital and royalty financing","length":108,"tagName":"p"}]},{"val":[{"type":"text","content":"Conference call and webcast December 15, 8:00 a.m. ET","length":53,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":404,"olType":false},{"type":"text","content":"MONTREAL and CHARLOTTE, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that the U.S. Food and Drug Administration (FDA) approved its first commercial product, CARDAMYST™ (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. This approval marks the first time that more than two million Americans with PSVT will have a rapid-acting treatment option they can self-administer outside the emergency department or other healthcare setting. CARDAMYST is expected to be available in retail pharmacies in the first quarter of 2026.","length":708,"tagName":"p"},{"type":"image","alt":"Cardamyst_Case_Product_inCase - Dec 2025[59]","displaySize":"","headline":null,"caption":"Cardamyst_Case_Product_inCase - Dec 2025[59]","className":"","disableSlideshowImg":false,"size":{"original":{"width":1647,"height":2235,"url":"h...